カテゴリ： GlobalData, フランス, 企業調査

Abivax SA (ABVX)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Abivax SA (ABVX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8014127
◆発行会社（調査会社）：GlobalData
◆発行日：2017年11月22日
◆ページ数：49
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：フランス
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Abivax SA (Abivax) is a biotechnology company that researches, develops and commercializes anti-viral therapies and therapeutic vaccines for the treatment of infectious diseases. The company’s pipeline products comprise ABX464, a small molecule against HIV; ABX311 for chikungunya; ABX544 to treat EBOLA virus infection; and ABX196, an immune enhancer candidate for vaccination. The company leverages three technology platforms for drug discovery antiviral, immune enhancing and polyclonal antibodies. It has collaborations with research institutions, cancer agencies, universities and other drug developers. Abivax is headquartered in Paris, France.

Abivax SA (ABVX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Abivax SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Abivax SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Abivax SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Abivax SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Abivax SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Abivax SA, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Evotec and Abivax Enter into Partnership 11
ABIVAX Enters into Co-Marketing Agreement with Finlay Institute 12
Licensing Agreements 13
ExpreS2ion Biotech to Enter into Licensing Agreement with Abivax 13
Heber Biotec Enters Into Licensing Agreement with Abivax 14
ABIVAX Enters into Licensing Agreement with CIGB for ABX203 15
Equity Offering 16
Abivax to Raise USD14 Million in Public Offering of Shares 16
Abivax Raises USD65 Million in IPO 17
Abivax SA – Key Competitors 18
Abivax SA – Key Employees 19
Abivax SA – Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Recent Developments 21
Financial Announcements 21
Sep 20, 2017: ABIVAX First-Half 2017 Financial Results and Update 21
Mar 15, 2017: ABIVAX Announces 2016 Full-Year Results and Progress Report 24
Sep 20, 2016: ABIVAX Provides Corporate Update and Reports 2016 Half Year Financial Results 27
Mar 15, 2016: ABIVAX – 2015 Full-Year Results and Progress Report 29
Corporate Communications 31
Oct 05, 2017: ABIVAX expands Scientific Advisory Board with appointment of renowned virologist and former President of the Pasteur Institute, Prof. Christian Brechot 31
Dec 15, 2016: ABIVAX appoints Didier Blondel as Chief Financial Officer 32
Government and Public Interest 33
Jan 09, 2017: ABIVAX to receive €8.4 million from Bpifrance “Invest in the Future Program” (PIA) for the development of innovative antiviral drugs 33
Product News 34
11/22/2016: ABIVAX to Host Key Opinion Leader Luncheon for Investors Focused on Novel Approaches to HIV Therapy 34
10/11/2016: ABIVAX Announces R&D Day at Company’s New Collaborative Laboratory in Montpellier 35
04/27/2016: ABIVAX Abstract on ABX464 Selected for Presentation at the AIDS 2016 Conference in Durban, South Africa 36
Feb 23, 2017: ABIVAX Has Discovered Novel Antiviral Molecules with Potential for Dengue Virus Treatment 37
Clinical Trials 38
Apr 04, 2017: ABIVAX initiates clinical trial (ABX464-005) to evaluate the effect of ABX464 on HIV-reservoirs in HIV Patients 38
Feb 02, 2017: Phase I Clinical Data of ABX464, ABIVAX’s First-in-Class anti-HIV Drug, Published in Two Articles in Peer-Reviewed Journals 39
Dec 08, 2016: ABIVAX Reports New Preclinical Data Supporting ABX464 as HIV Functional Cure and Novel Treatment for Inflammatory Diseases at HIV DART Meeting 40
Dec 06, 2016: ABIVAX provides update on clinical development program for ABX464 for functional cure of patients with HIV-infection 41
Nov 16, 2016: ABIVAX to Present Phase IIa Clinical Data on ABX464 during NIH/NIAID-Sponsored Strategies for an HIV Cure Meeting 2016 42
Oct 27, 2016: ABIVAX presented this week new pre-clinical data on ABX464 during scientific conference on “HIV Drug Therapy” in Glasgow, Scotland 43
Sep 13, 2016: ABIVAX Completes the Second Milestone in CaReNa, a “Strategic Industrial Innovation Project” Supported by Bpifrance 44
May 30, 2016: Ongoing Clinical Development of ABX464: ABIVAX Launches ABX464-004 Study 45
Apr 19, 2016: ABIVAX Obtains Regulatory and Ethics Clearance in Spain to Begin Second Phase IIa Clinical Trial For ABX464 In HIV/AIDS Patients 46
Jan 21, 2016: ABIVAX to present at the prestigious Conference on Retroviruses and Opportunistic Infections (CROI) positive top-line clinical Phase IIa data for novel HIV drug-candidate ABX464 47
Jan 11, 2016: ABIVAX announces positive top-line clinical Phase IIa data for novel HIV drug-candidate ABX464 48
Appendix 49
Methodology 49
About GlobalData 49
Contact Us 49
Disclaimer 49

List of Tables
Abivax SA, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Abivax SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Abivax SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Abivax SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Abivax SA, Deals By Therapy Area, 2011 to YTD 2017 9
Abivax SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Evotec and Abivax Enter into Partnership 11
ABIVAX Enters into Co-Marketing Agreement with Finlay Institute 12
ExpreS2ion Biotech to Enter into Licensing Agreement with Abivax 13
Heber Biotec Enters Into Licensing Agreement with Abivax 14
ABIVAX Enters into Licensing Agreement with CIGB for ABX203 15
Abivax to Raise USD14 Million in Public Offering of Shares 16
Abivax Raises USD65 Million in IPO 17
Abivax SA, Key Competitors 18
Abivax SA, Key Employees 19
Abivax SA, Other Locations 20

★海外企業調査レポート[Abivax SA (ABVX)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Alfa Laval AB (ALFA)：企業の財務・戦略的SWOT分析
    Alfa Laval AB (ALFA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • California Water Service Group (CWT)：企業の財務・戦略的SWOT分析
    Summary California Water Service Group (California Water Service) is a utility service provider that offers wastewater services and water operation and maintenance services. The utility provides services such as water and wastewater utility services, and operating water and wastewater systems servic …
  • Penske Corporation：企業の戦略的SWOT分析
    Penske Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • AeroCentury Corp：企業の戦略・SWOT・財務分析
    AeroCentury Corp - Strategy, SWOT and Corporate Finance Report Summary AeroCentury Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • AEON Co Ltd (8267)：企業の財務・戦略的SWOT分析
    AEON Co Ltd (8267) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Ingram Micro Inc.：企業のM&A・事業提携・投資動向
    Ingram Micro Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Ingram Micro Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • Safety-Kleen Inc：企業の戦略的SWOT分析
    Safety-Kleen Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Ossur hf (OSSR)：企業の財務・戦略的SWOT分析
    Ossur hf (OSSR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Rubius Therapeutics Inc (RUBY)：製薬・医療：M&Aディール及び事業提携情報
    Summary Rubius Therapeutics Inc (Rubius Therapeutics) is a biotechnology company that focuses on the development of medicines for the treatment of rare diseases, cancer and autoimmune diseases. The company through its rubius erythrocyte design (RED) platform engineer and culture Red Cell Therapeutic …
  • Petroliam Nasional Bhd：石油・ガス：M&Aディール及び事業提携情報
    Summary Petroliam Nasional Bhd (Petronas) is an integrated oil and gas company that explores, develops and produces of oil and natural gas in Malaysia and overseas. It also carries out downstream operations such as processing and liquefaction of natural gas; refining and marketing of petroleum produ …
  • Vectrus Inc (VEC)：企業の財務・戦略的SWOT分析
    Vectrus Inc (VEC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Lupin Ltd (LUPIN)：製薬・医療：M&Aディール及び事業提携情報
    Summary Lupin Ltd (Lupin) focuses on the development and manufacture of generic and branded formulations, biotechnology products and active pharmaceutical ingredients (APIs). The company has expertise in the areas of cardiovascular, asthma, diabetology, pediatrics, central nervous system, gastro-int …
  • Brookfield Renewable Energy Partners LP (BEP.UN)：企業の財務・戦略的SWOT分析
    Brookfield Renewable Energy Partners LP (BEP.UN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key s …
  • Nufarm Ltd (NUF)：企業の財務・戦略的SWOT分析
    Nufarm Ltd (NUF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Cal-Maine Foods Inc (CALM)：企業の財務・戦略的SWOT分析
    Cal-Maine Foods Inc (CALM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • High Arctic Energy Services Inc (HWO)：石油・ガス：M&Aディール及び事業提携情報
    Summary High Arctic Energy Services Inc (High Arctic) is an oil and gas company that provides drilling services and equipment for rentals. The company provides services such as drilling services, matting and equipment rentals, snubbing services and nitrogen services. It offers equipment rentals of l …
  • Biogen Inc (BIIB)-製薬・医療分野：企業M&A・提携分析
    Summary Biogen Inc (Biogen) is a global biotechnology company that manufactures and markets drugs for the treatment of neurodegenerative diseases and rare and autoimmune disorders. Its marketed products include Avonex (interferon beta-1a), Tysabri (natalizumab), Tecfidera (dimethyl fumarate), Zinbry …
  • Del Taco Holdings, Inc.：戦略・SWOT・企業財務分析
    Del Taco Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary Del Taco Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Bunzl plc (BNZL)：企業の財務・戦略的SWOT分析
    Bunzl plc (BNZL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Vietnam Dairy Products Joint Stock Co：企業の戦略・SWOT・財務情報
    Vietnam Dairy Products Joint Stock Co - Strategy, SWOT and Corporate Finance Report Summary Vietnam Dairy Products Joint Stock Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆